Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.
Also called NCT01763905
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 307 participants
- Sponsor
- Registry
-
NCT01763905 -
2012-001364-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong SAR China, Netherlands, Poland, South Africa, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01763905. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-24 (actual); primary completion 2013-11-19 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
- Acronym
- GAUSS-2
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Placebo to Evolocumab
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebo to Ezetimibe
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01763905- Content hash
098500c5070b95470756ea9149a37937f6a9d1aac3945426fbb72c87ee26f83d